Posted by Michael Wonder on 17 Feb 2017
FDA expands approval of Spriva Respimat (tiotropium bromide) inhalation spray for maintenance treatment of asthma in children
16 February 2017 - Supplemental new drug application approved under priority review from the FDA.
Boehringer Ingelheim today announced that the U.S. FDA approved Spiriva Respimat for the long-term, once-daily maintenance treatment of asthma in people age 6 and older. Spiriva Respimat is not a treatment for sudden asthma symptoms.
The FDA approved the Supplemental new drug aapplication under a priority review designation, and the FDA also granted paediatric exclusivity to Spirava Respimat in light of the clinical trials conducted by Boehringer Ingelheim.
